DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, +13

Clinical Cancer Research

A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Yuuri Hashimoto, Kumiko Koyama, Yasuki Kamai, +20

Clinical Cancer Research

Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads

Takashi Nakada, Takeshi Masuda, Hiroyuki Naito, +9

Bioorganic & Medicinal Chemistry Letters

MedicineRadiation OncologyAntibody EngineeringImmunotherapeutics

Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology

Yusuke Ogitani, Yuki Abe, Takuma Iguchi, +12

Bioorganic & Medicinal Chemistry Letters

Wide ApplicationMedicinal ChemistryDrug TargetingPolymer-drug ConjugateMedicine +10

Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody–Drug Conjugate

Kenji Iida, Amr H. Abdelhamid Ahmed, Akiko Kawano Nagatsuma, +21

Cancer Discovery

Masking of the Fc region in human IgG4 by constrained X-ray scattering modelling: implications for antibody function and therapy

Yuki Abe, Jayesh Gor, Daniel G. Bracewell, +2

Biochemical Journal

Anti‐tumor effects of mAb against <scp>l</scp>‐type amino acid transporter 1 (<scp>LAT</scp>1) bound to human and monkey <scp>LAT</scp>1 with dual avidity modes

Shiho Ueda, Hidemi Hayashi, Takako Miyamoto, +13

Cancer Science

A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1

Masashi Numata, Noriyasu Haginoya, Machiko Shiroishi, +34

Cancer Cell International

Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models

Hirokazu Suzuki, Shotaro Nagase, C. Saito, +11

Molecular Cancer Therapeutics

Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd.

Daisuke Okajima, Satoru Yasuda, Yusuke Yokouchi, +13

Journal of Clinical Oncology

Novel Dna TopoisomeraseImmunologyImmunotherapyCancer BiologyTumor Biology +18